Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

被引：17
|
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Mikhailidis, Dimitri P. [2 ]
Mantzoros, Christos [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] UCL, Royal Free Hosp Campus, Med Sch, Dept Clin Biochem, London, England
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2017年 / 74卷
关键词：
GENETIC-VARIANTS; REDUCING LIPIDS; STATIN THERAPY; MANAGEMENT; EVOLOCUMAB; EFFICACY; SAFETY; DYSLIPIDEMIA; ASSOCIATION; ALIROCUMAB;
D O I：
10.1016/j.metabol.2017.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 46
页数：4
相关论文
共 50 条
  • [41] The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia
    Tziomalos, Konstantinos
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (10) : 1495 - 1499
  • [42] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor use in the management of resistant hypercholesterolemia induced by mitotane treatment for adrenocortical cancer
    Tsakiridou, Efthymia D.
    Liberopoulos, Evangelos
    Giotaki, Zoe
    Tigas, Stelos
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (03) : 826 - 829
  • [43] Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors
    Nelson, Christopher P.
    Lai, Florence Y.
    Nath, Mintu
    Ye, Shu
    Webb, Thomas R.
    Schunkert, Heribert
    Samani, Nilesh J.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2019, 12 (01): : E002196
  • [44] Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations
    Tada, Hayato
    Kawashiri, Masa-aki
    Yoshida, Taiji
    Teramoto, Ryota
    Nohara, Atsushi
    Konno, Tetsuo
    Inazu, Akihiro
    Mabuchi, Hiroshi
    Yamagishi, Masakazu
    Hayashi, Kenshi
    CIRCULATION JOURNAL, 2016, 80 (02) : 512 - +
  • [45] Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
    Ashraf Reda
    Ahmed Shawky Elserafy
    Elsayed Farag
    Tamer Mostafa
    Nabil Farag
    Atef Elbahry
    Osama Sanad
    Ahmed Bendary
    Ahmed Elkersh
    Mohammed Selim
    Morad Beshay
    Hazem Khamis
    The Egyptian Heart Journal, 72
  • [46] PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke PheWAS, TreWAS, and More
    Sullivan, David
    Bonnitcha, Paul
    Spinks, Catherine
    Keech, Tony
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2018, 11 (07):
  • [47] Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Concentration and Risk of Cardiovascular Events - Systematic Review and Meta-Analysis of Prospective Studies
    Xiao, Yunjun
    Peng, Chaoqiong
    Huang, Wei
    Zhang, Jinzhou
    Gao, Yang
    Kim, Jean H.
    Yeoh, Eng-kiong
    Su, Xuefen
    CIRCULATION JOURNAL, 2017, 81 (08) : 1150 - 1157
  • [48] Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease
    Farrah, Tariq E.
    Anand, Atul
    Gallacher, Peter J.
    Kimmitt, Robert
    Carter, Edwin
    Dear, James W.
    Mills, Nicholas L.
    Webb, David J.
    Dhaun, Neeraj
    HYPERTENSION, 2019, 74 (02) : 323 - 330
  • [49] Real-world lipid lowering effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: A single-centre study
    Han, J.
    Bilgrami, S.
    Ross, S.
    Broadhead, H.
    Attar, N.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 322 : 240 - 244
  • [50] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia
    Ferri, Nicola
    Ruscica, Massimiliano
    ENDOCRINE, 2016, 54 (03) : 588 - 601
12345